Coordinated existence of multiple gangliosides is required for cartilage metabolism.
Coordinated existence of multiple gangliosides is required for cartilage metabolism.
复制标题
软骨代谢需要多种神经节苷脂的协调存在。
DOI:
10.1016/j.joca.2018.11.003
复制
发表时间:
2019
影响因子:
7
通讯作者:
Iwasaki Norimasa.
中科院分区:
文献类型:
--
作者:
Momma Daisuke;Onodera Tomohiro;Homan Kentaro;Matsubara Shinji;Sasazawa Fumio;Furukawa Junichi;Matsuoka Masatake;Yamashita Tadashi;Iwasaki Norimasa.
ObjectiveGangliosides, ubiquitously existing membrane components that modulate transmembrane signaling and mediate cell-to-cell and cell-to-matrix interactions, are key molecules of inflammatory and neurological disorders. However, the functions of gangliosides in the cartilage degradation process remain unclear. We investigated the functional role of gangliosides in cartilage metabolism related to osteoarthritis (OA) pathogenesis.DesignWe generated knockout (KO) mice by targeting the β1, 4-N-acetylgalactosaminyltransferase (GalNAcT) gene, which encodes an enzyme of major gangliosides synthesis, and the GD3 synthase (GD3S) gene, which encodes an enzyme of partial gangliosides synthesis.In vivoOA andin vitrocartilage degradation models were used to evaluate the effect of gangliosides on the cartilage degradation process.ResultsTheGalNAcTandGD3SKO mice developed and grew normally; nevertheless, OA changes in these mice were enhanced with aging. TheGalNAcTKO mice showed significantly enhanced OA progression compared toGD3Smicein vivo. BothGalNAcTandGD3SKO mice showed severe IL-1α–induced cartilage degradationex vivo. Phosphorylation of MAPKs was enhanced in bothGalNAcTandGD3SKOs after IL-1α stimulation. Gangliosides modulated byGalNAcTorGD3Srescued an increase of MMP-13 induced by IL-1α in mice lackingGalNAcTorGD3Safter exogenous replenishmentin vitro.ConclusionThese data show that the deletion of gangliosides in mice enhanced OA development. Moreover, the gangliosides modulated byGalNAcTare important for cartilage metabolism, suggesting thatGalNAcTis a potential target molecule for the development of novel OA treatments.